


WALDER WYSS ADVISES PFIZER ON ITS INVESTMENT IN ANOKION

Posted on 30 November 2022



Category: [Corporate](#)

Tags: [Pfizer](#), [Samuel Lieberherr](#), [sx3](#), [Timon Nydegger](#), [Urs Schenker](#), [Walder Wyss](#)



As we have informed [here](#) last 10 November 2022, the clinical-stage biotechnology company **Anokion** has closed an USD 35 million equity investment from **Pfizer** through the Pfizer Breakthrough Growth Initiative. The Biotech company is focus on the treating autoimmune disease by restoring normal immune tolerance.

[Walder Wyss](#) has also advised on the deal acting as Swiss legal advisor to Pfizer. The team included **Urs Schenker** (counsel, pictured left), **Samuel Lieberherr** (managing associate, pictured center) and **Timon Nydegger** (senior associate, pictured right), all corporate/m&a.